Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
16 06 2023
Historique:
received: 08 11 2022
accepted: 26 05 2023
medline: 19 6 2023
pubmed: 17 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

COVID-19 has stimulated the rapid development of new antibody and small molecule therapeutics to inhibit SARS-CoV-2 infection. Here we describe a third antiviral modality that combines the drug-like advantages of both. Bicycles are entropically constrained peptides stabilized by a central chemical scaffold into a bi-cyclic structure. Rapid screening of diverse bacteriophage libraries against SARS-CoV-2 Spike yielded unique Bicycle binders across the entire protein. Exploiting Bicycles' inherent chemical combinability, we converted early micromolar hits into nanomolar viral inhibitors through simple multimerization. We also show how combining Bicycles against different epitopes into a single biparatopic agent allows Spike from diverse variants of concern (VoC) to be targeted (Alpha, Beta, Delta and Omicron). Finally, we demonstrate in both male hACE2-transgenic mice and Syrian golden hamsters that both multimerized and biparatopic Bicycles reduce viraemia and prevent host inflammation. These results introduce Bicycles as a potential antiviral modality to tackle new and rapidly evolving viruses.

Identifiants

pubmed: 37328472
doi: 10.1038/s41467-023-39158-1
pii: 10.1038/s41467-023-39158-1
pmc: PMC10275983
doi:

Substances chimiques

Antiviral Agents 0
Peptides 0
Antibodies 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3583

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : U105181010
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 223054/Z/21/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 214344/A/18/Z
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Nat Protoc. 2018 Dec;13(12):2991-3017
pubmed: 30455477
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
N Engl J Med. 2021 Oct 7;385(15):1382-1392
pubmed: 34260849
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Acta Crystallogr D Biol Crystallogr. 2005 Apr;61(Pt 4):458-64
pubmed: 15805601
Nat Chem Biol. 2009 Jul;5(7):502-7
pubmed: 19483697
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
J Med Chem. 2020 Apr 23;63(8):4107-4116
pubmed: 32202781
AAPS J. 2015 Jan;17(1):134-43
pubmed: 25366889
Br J Clin Pharmacol. 2023 Mar;89(3):1105-1114
pubmed: 36214216
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
Clin Microbiol Infect. 2022 Sep;28(9):1297-1299
pubmed: 35595125
PLoS Pathog. 2021 Jan 25;17(1):e1009246
pubmed: 33493182
Nat Chem Biol. 2023 Mar;19(3):284-291
pubmed: 36411391
J Med Chem. 2022 Nov 10;65(21):14337-14347
pubmed: 36204777
N Engl J Med. 2022 Apr 14;386(15):1477-1479
pubmed: 35263515
Nat Struct Mol Biol. 2020 Oct;27(10):934-941
pubmed: 32737467
N Engl J Med. 2022 Feb 10;386(6):509-520
pubmed: 34914868
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Clin Infect Dis. 2023 Feb 8;76(3):408-415
pubmed: 36189631
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Sci Adv. 2021 Mar 10;7(11):
pubmed: 33692109
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Viruses. 2022 Oct 12;14(10):
pubmed: 36298797
N Engl J Med. 2022 Jan 27;386(4):305-315
pubmed: 34937145
Antimicrob Agents Chemother. 2021 Mar 1;65(5):
pubmed: 33649113
Pharmacol Res. 2020 Aug;158:104899
pubmed: 32407959
N Engl J Med. 2021 Dec 2;385(23):e81
pubmed: 34587383
JAMA. 2022 Sep 20;328(11):1104-1107
pubmed: 35913747
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
J Immunother Cancer. 2021 Nov;9(11):
pubmed: 34725211
Viruses. 2019 Apr 04;11(4):
pubmed: 30987343
Lancet. 2021 May 29;397(10289):2024-2025
pubmed: 34000255
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
PLoS Pathog. 2008 Jul 25;4(7):e1000109
pubmed: 18654624
Clin Infect Dis. 2023 Feb 8;76(3):e507-e509
pubmed: 35867699
J Med Chem. 2012 Nov 26;55(22):10187-97
pubmed: 23088498
Nature. 2020 Dec;588(7837):327-330
pubmed: 32942285
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Acta Crystallogr D Struct Biol. 2017 Feb 1;73(Pt 2):112-122
pubmed: 28177307
Clin Microbiol Infect. 2023 Feb;29(2):240-246
pubmed: 36067943
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Bioconjug Chem. 2012 Sep 19;23(9):1856-63
pubmed: 22812498
Curr Opin Virol. 2021 Aug;49:36-40
pubmed: 34029993
Sci Transl Med. 2022 Jan 19;14(628):eabl7430
pubmed: 34941423
Bioconjug Chem. 2022 Aug 17;33(8):1441-1445
pubmed: 35894801
J Med Chem. 2018 Apr 12;61(7):2823-2836
pubmed: 29517911
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Nature. 2023 Jan;613(7944):558-564
pubmed: 36351451
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
J Med Chem. 2022 Jul 28;65(14):9858-9872
pubmed: 35819182
Nat Biotechnol. 2022 Dec;40(12):1845-1854
pubmed: 35864170

Auteurs

Katherine U Gaynor (KU)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Marina Vaysburd (M)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.

Maximilian A J Harman (MAJ)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Anna Albecka (A)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.

Phillip Jeffrey (P)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Paul Beswick (P)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Guido Papa (G)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.

Liuhong Chen (L)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Donna Mallery (D)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.

Brian McGuinness (B)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Katerine Van Rietschoten (K)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Steven Stanway (S)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom.

Paul Brear (P)

Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom.

Aleksei Lulla (A)

Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom.

Katarzyna Ciazynska (K)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.

Veronica T Chang (VT)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.

Jo Sharp (J)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Megan Neary (M)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Helen Box (H)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Jo Herriott (J)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Edyta Kijak (E)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Lee Tatham (L)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Eleanor G Bentley (EG)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Parul Sharma (P)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Adam Kirby (A)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Ximeng Han (X)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

James P Stewart (JP)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

Andrew Owen (A)

University of Liverpool, Crown Street, Liverpool, L69 7ZD, United Kingdom.

John A G Briggs (JAG)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom.
Max Planck Institute of Biochemistry, Martinsried, 82152, Germany.

Marko Hyvönen (M)

Department of Biochemistry, University of Cambridge, Cambridge, CB2 1GA, United Kingdom.

Michael J Skynner (MJ)

Bicycle Therapeutics, Portway Building, Granta Park, Cambridge, CB21 6GS, United Kingdom. michael.skynner@bicycletx.com.

Leo C James (LC)

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge, CB2 0QH, United Kingdom. lcj@mrc-lmb.cam.ac.uk.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH